A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE-ACS Trial.

May 2011 - EuroPCR Late Breaking Trials - Paris
During the late-breaking clinical trials sessions held in the main arena during the EuroPCR 2011 congress, the results of the multicenter, prospective, randomised controlled trial "BASE-ACS" were presented by Dr Pasi Karjalainen (Heart center, Satakunta Hospital, Pori, Finland).
View document (pdf file, 202Kb)

One Year Clinical Outcome of the 2000 Patients Enrolled in the Coronary Angioplasty Acute Myocardial Infarction Titan2 Bio Active Stent Registry: The CATS-AMI Registry.

May 2011 - EuroPCR Late Breaking Trials - Paris
During the late breaking registries and trial updates sessions held during the EuroPCR 2011 congress, the results of the large scale, multicenter, prospective registry "CATS-AMI" were presented by Dr Michaël Angioi (Institut Lorrain du Coeur et des Vaisseaux, Nancy University Hospital, France).
View document (pdf file, 200Kb)

Titanium-Nitride-Oxide Bio Active Technology in ACS Patients: Present and Future

May 2011 - EuroPCR Symposium - Paris
The learning objectives of this key Scientific Symposium held during the EuroPCR 2011 congress were to review why Acute Coronary Syndrome patients are still a challenging indication for PCI, to understand the Titanium-Nitride-Oxide coated stents potential interest for ACS patients and to describe the latest TITAN2 bio-active stent clinical data and finally to share the next coming applications of this technology.
View document (pdf file, 200Kb)

Hexacath, France, announces that TITAN2 the first BAS (Bio Active Stent) has been awarded a level III official reimbursement approval in France.

September 5, 2006 - Barcelona
The information was published in the French Government Journal "Journal Officiel de la République Française" in april 2006. Hexacath is proud to make available to physicians and patients around the world its unique patented Titanium-Nitride-Oxide technology which has been proven to significantly reduce restenosis and MACE (Major Adverse Cardiac Event) at follow up versus Bare Metal Stents.
View document (pdf file, 22Kb)

TITAN stent vs TAXUS stent

October 20, 2005 - Washington DC
Dr Pasi Karjalainen from Satakunta Hospital Pori Hospital in Finland presented the data about the Titan stent Pori Registry during the Cardiovascular Research Foundation's 17th Annual Transcatheter Cardiovascular Therapeutics (TCT 2005) scientific symposia moderated by Dr E.Grube.
View document (pdf file, 19Kb)